VEGFA and cancer: A possible way to improve these limited immunotherapy benefits include combination with other types of therapy (similar to other types of cancer patients treated with PD-1 or PD-L1 antibodies) such as chemotherapy, vascular endothelial growth factor (VEGF) pathway targeting drugs, or other immune checkpoint inhibitors that ideally do not substantially increase overall toxicity.